ArticleCureus2026
Pigmented Contact Dermatitis to Cosmetics: A Prospective Observational Study From a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Pigmented contact dermatitis (PCD) is a pigmentary variant of contact dermatitis characterized by gradually developing facial hyperpigmentation with minimal or absent overt dermatitis. Owing to its close resemblance to other causes of facial melanosis, PCD is frequently underdiagnosed. Patch testing plays a crucial role in identifying causative allergens and guiding avoidance-based management. Objectives To evaluate the clinical profile, dermoscopic features, and patch test allergen spectrum in patients with PCD attending a tertiary care hospital. Methods This prospective observational study was conducted over a period of 1.5 years in the Department of Dermatology, Santosh Medical College and Hospital, Ghaziabad. A total of 55 patients clinically diagnosed with PCD and fulfilling inclusion criteria were enrolled after informed consent. Detailed demographic and clinical data were recorded using a structured proforma. Dermatoscopic examination was performed using a DermLite DL5 dermoscope (DermLite LLC, Aliso Viejo, CA). Patch testing was carried out using the Indian Standard Battery and Indian Cosmetic Series, with readings taken at 48 hours, 96 hours, and on day 7, interpreted according to ICDRG criteria. Statistical analysis was performed using IBM SPSS version 27.0. Results The majority of patients were women (n=41; 74.5%), with the commonest age group being 31-40 years (n=23; 41.8%). Brownish-black pigmentation was the predominant clinical presentation. Dermatoscopy most frequently revealed brownish-gray background pigmentation, brown and gray globules, and follicular plugs with perifollicular white halos. Patch test positivity to at least one allergen was observed in 43 (78.2%) patients. Paraphenylenediamine (n=16; 27.1%) was the most common allergen, followed by cetrimide (n=9; 15.3%) and lavender absolute (n=7; 11.9%). Hair dye was the most frequent exposure source associated with allergen positivity. Conclusion: PCD predominantly affects young to middle-aged females and is strongly associated with cosmetic and hair dye exposure. Patch testing is an essential diagnostic tool for identifying relevant allergens and enabling effective prevention through targeted avoidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.